PerspectiveCancer Biomarkers

Parallel Paths to Predictive Biomarkers in Oncology: Uncoupling of Emergent Biomarker Development and Phase III Trial Execution

See allHide authors and affiliations

Science Translational Medicine  09 Dec 2009:
Vol. 1, Issue 10, pp. 10ps11
DOI: 10.1126/scitranslmed.3000287

You are currently viewing the abstract.

View Full Text

Log in to view the full text

Log in through your institution

Log in through your institution


It is within pivotal phase III clinical trials that predictive biomarkers have the greatest potential to affect clinical practice by targeting drugs under development to relevant patient subgroups. Predictive biomarkers can be integrated into phase III clinical trials by a variety of approaches, including trial designs that uncouple the processes and actively anticipate the emergence of new biomarkers during trial execution. Here we describe the various approaches in an oncology context.


  • Citation: R. Sikorski, B. Yao, Parallel paths to predictive biomarkers in oncology: Uncoupling of emergent biomarker development and phase III trial execution. Sci. Transl. Med. 1, 10ps11 (2009).

View Full Text

Stay Connected to Science Translational Medicine